ADA, EASD 2022 Consensus Report from the Primary Care Point of View, with Nisa Maruthur, MD, MHS
ADA/EASD Calls for Wide Systemic Change to Address Impact of Social Determinants of Health
Clinical Practice Guidelines Could be More Primary Care-friendly, says Nisa Maruthur, MD, MHS
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
2 Commerce Drive
Cranbury, NJ 08512